Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2004

01-04-2004 | Article

CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines

Authors: O. Vosters, C. Beuneu, N. Nagy, B. Movahedi, E. Aksoy, I. Salmon, D. Pipeleers, M. Goldman, V. Verhasselt

Published in: Diabetologia | Issue 4/2004

Login to get access

Abstract

Aims/hypothesis

Human pancreatic duct cells are closely associated with islet beta cells, and contaminate islet suspensions transplanted in Type 1 diabetes mellitus patients. Activated duct cells produce cytotoxic mediators and possibly contribute to the pathogenesis of Type 1 diabetes mellitus or islet graft rejection. As CD40 transduces activation signals involved in inflammatory and immune disorders, we investigated CD40 expression on duct cells and their response to CD40 engagement.

Methods

CD40 expression on human pancreatic duct cells was analysed by flow cytometry and immunohistochemical analyses. To assess the function of CD40 expression on duct cells, activation of the transcription factor nuclear factor-kappa B was determined using electrophoretic mobility shift assay and ELISA. Cytokine mRNA levels were quantified by real-time RT-PCR, and protein levels by Luminex technology.

Results

Isolated human pancreatic duct cells and Capan-2 cell lines were found to express constitutively CD40. The expression of CD40 on duct cells was confirmed in vivo on human normal and pathological pancreatic specimens. CD40 ligation on Capan-2 cells induced rapid nuclear factor-kappa B activation, and supershift assays demonstrated that p50/p65 heterodimers and p50/p50 homodimers were present in the activated complexes in the nucleus. This activation was accompanied by tumour necrosis factor-α and interleukin-1β mRNA accumulation. Tumour necrosis factor-α protein secretion was confirmed in CD40-activated Capan-2 cells and in isolated human pancreatic duct cells.

Conclusions/interpretation

Interaction between activated T lymphocytes expressing CD40 ligand and duct cells expressing CD40 may contribute to the immune responses involved in Type 1 diabetes mellitus and islet graft rejection. Interfering with CD40-mediated duct cell activation could alleviate beta cell damage of immune origin.
Literature
1.
Bouwens L, Pipeleers DG (1998) Extra-insular beta cells associated with ductules are frequent in adult human pancreas. Diabetologia 41:629–633PubMed
2.
Bonner-Weir S, Baxter LA, Schuppin GT, Smith FE (1993) A second pathway for regeneration of adult exocrine and endocrine pancreas. A possible recapitulation of embryonic development. Diabetes 42:1715–1720PubMed
3.
Pavlovic D, Winkel M van de, Auwera B van der et al. (1997) Effect of interferon-gamma and glucose on major histocompatibility complex class I and class II expression by pancreatic beta- and non-beta-cells. J Clin Endocrinol Metab 82:2329–2336CrossRefPubMed
4.
Pavlovic D, Chen MC, Bouwens L, Eizirik DL, Pipeleers D (1999) Contribution of ductal cells to cytokine responses by human pancreatic islets. Diabetes 48:29–33
5.
Bonner-Weir S, Taneja M, Weir GC et al. (2000) In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA 97:7999–8004CrossRefPubMed
6.
Bogdani M, Lefebvre V, Buelens N et al. (2003) Formation of insulin-positive cells in implants of human pancreatic duct cell preparations from young donors. Diabetologia 46:830–838CrossRefPubMed
7.
Gao R, Ustinov J, Pulkkinen MA, Lundin K, Korsgren O, Otonkoski T (2003) Characterisation of endocrine progenitor cells and critical factors for their differentiation in human adult pancreatic cell culture. Diabetes 52:2007–2015PubMed
8.
Pipeleers D, Hoorens A, Marichal-Pipeleers M, Van de Casteele M, Bouwens L, Ling Z (2001) Role of pancreatic beta-cells in the process of beta-cell death. Diabetes 50 [Suppl 1]:S52–S57
9.
Ling Z, Pipeleers DG (1996) Prolonged exposure of human beta cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation. J Clin Invest 98:2805–2812PubMed
10.
Keymeulen B, Ling Z, Gorus FK et al. (1998) Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 41:452–459CrossRefPubMed
11.
Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216
12.
Vives-Pi M, Somoza N, Fernandez-Alvarez J et al. (2003) Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells. Clin Exp Immunol 133:208–218CrossRefPubMed
13.
Woltman AM, Haij S de, Boonstra JG, Gobin SJ, Daha MR, Kooten C van (2000) Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol 11:2044–2055PubMed
14.
Propst SM, Denson R, Rothstein E, Estell K, Schwiebert LM (2000) Proinflammatory and Th2-derived cytokines modulate CD40-mediated expression of inflammatory mediators in airway epithelia: implications for the role of epithelial CD40 in airway inflammation. J Immunol 165:2214–2221PubMed
15.
Afford SC, Ahmed-Choudhury J, Randhawa S et al. (2001) CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signalling in human intrahepatic biliary epithelial cells. FASEB J 15:2345–2354CrossRefPubMed
16.
Propst SM, Estell K, Schwiebert LM (2002) CD40-mediated activation of NF-kappa B in airway epithelial cells. J Biol Chem 277:37054–37063CrossRefPubMed
17.
Haij S de, Woltman AM, Bakker AC, Daha MR, Kooten C van (2002) Production of inflammatory mediators by renal epithelial cells is insensitive to glucocorticoids. Br J Pharmacol 2002 137:197–204
18.
Amsellem C, Durieu, Chambe MT, Peyrol S, Pacheco Y (2002) In vitro expression of fas and CD40 and induction of apoptosis in human cystic fibrosis airway epithelial cells. Respir Med 96:244–249CrossRefPubMed
19.
Berberich I, Shu GL, Clark EA (1994) Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol 153:4357–4366PubMed
20.
Kooten C van, Banchereau J (1997) Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 9:330–337PubMed
21.
Kooten C van, Banchereau J (2000) CD40-CD40 ligand. J Leukoc Biol 67:2–17PubMed
22.
Henn V, Slupsky JR, Grafe M et al. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594CrossRefPubMed
23.
24.
Heeschen C, Dimmeler S, Hamm CW et al. (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104–1111CrossRefPubMed
25.
Caux C, Massacrier C, Vanbervliet B et al. (1994) Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180:1263–1272PubMed
26.
Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16:111–135PubMed
27.
O’Sullivan BJ, Thomas R (2002) CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kappaB. J Immunol 168:5491–5498PubMed
28.
Homann D, Jahreis A, Wolfe T et al. (2002) CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity 16:403–415PubMed
29.
Moore WV, Chu W, Tong PY et al. (2002) Prevention of autoimmune diabetes in the DRBB rat by CD40/154 blockade. J Autoimmun 19:139–145CrossRefPubMed
30.
De Breuck S, Lardon J, Rooman I, Bouwens L (2003) Netrin-1 expression in fetal and regenerating rat pancreas and its effect on the migration of human pancreatic duct and porcine islet precursor cells. Diabetologia 46:926–933CrossRefPubMed
31.
Aksoy E, Amraoui Z, Goriely S, Goldman M, Willems F (2002) Critical role of protein kinase C epsilon for lipopolysaccharide-induced IL-12 synthesis in monocyte-derived dendritic cells. Eur J Immunol 32:3040–3049CrossRefPubMed
32.
Osborn L, Kunkel S, Nabel GJ (1989) Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 86:2336–2340PubMed
33.
Stordeur P, Zhou L, Goldman M (2002) Analysis of spontaneous mRNA cytokine production in peripheral blood. J Immunol Methods 261:195–197CrossRefPubMed
34.
Stordeur P, Zhou L, Byl B et al. (2003) Immune monitoring in whole blood using real-time PCR. J Immunol Methods 276:69–77CrossRefPubMed
35.
May MJ, Ghosh S (1997) Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol 8:63–73PubMed
36.
Lee JI, Burckart GJ (1998) Nuclear factor kappa B: important transcription factor and therapeutic target. J Clin Pharmacol 38:981–993PubMed
37.
38.
Corbett JA, McDaniel ML (1995) Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase. J Exp Med 181:559–568PubMed
39.
Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA (1998) IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 102:516–526PubMed
40.
Ling Z, Van de Casteele M, Eizirik DL, Pipeleers DG (2000) Interleukin-1beta-induced alteration in a beta-cell phenotype can reduce cellular sensitivity to conditions that cause necrosis but not to cytokine-induced apoptosis. Diabetes 49:340–345
41.
Hoorens A, Stange G, Pavlovic D, Pipeleers D (2001) Distinction between interleukin-1-induced necrosis and apoptosis of islet cells. Diabetes 50:551–557
42.
Thomas HE, Darwiche R, Corbett JA, Kay TW (2002) Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes 51:311–316PubMed
43.
Tabatabaie T, Vasquez-Weldon A, Moore DR, Kotake Y (2003) Free radicals and the pathogenesis of type 1 diabetes: beta-cell cytokine-mediated free radical generation via cyclooxygenase-2. Diabetes 52:1994–1999PubMed
44.
Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13:114–119
45.
46.
47.
Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H (1990) Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci USA 87:968–972PubMed
48.
Yang XD, Tisch R, Singer SM et al. (1994) Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 180:995–1004PubMed
49.
Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA (1996) Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 184:1963–1974PubMed
50.
Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Rajotte RV, Power RF (1997) TNF-alpha down-regulates type 1 cytokines and prolongs survival of syngeneic islet grafts in nonobese diabetic mice. J Immunol 159:6298–6303PubMed
51.
Green EA, Flavell RA (2000) The temporal importance of TNF-alpha expression in the development of diabetes. Immunity 12:459–469PubMed
52.
Christen U, Wolfe T, Mohrle U et al. (2001) A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis. J Immunol 166:7023–7032PubMed
53.
Skak K, Guerder S, Picarella DE, Brenden N, Flavell RA, Michelsen BK (2003) TNF-alpha impairs peripheral tolerance towards beta-cells, and local costimulation by B7.1 enhances the effector function of diabetogenic T cells. Eur J Immunol 33:1341–1350CrossRefPubMed
54.
Parker DC, Greiner DL, Phillips NE et al. (1995) Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 92:9560–9564PubMed
55.
Kover KL, Geng Z, Hess DM, Benjamin CD, Moore WV (2000) Anti-CD154 (CD40L) prevents recurrence of diabetes in islet isografts in the DR-BB rat. Diabetes 49:1666–1670PubMed
56.
Phillips NE, Markees TG, Mordes JP, Greiner DL, Rossini AA (2003) Blockade of CD40-mediated signalling is sufficient for inducing islet but not skin transplantation tolerance. J Immunol 170:3015–3023PubMed
Metadata
Title
CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines
Authors
O. Vosters
C. Beuneu
N. Nagy
B. Movahedi
E. Aksoy
I. Salmon
D. Pipeleers
M. Goldman
V. Verhasselt
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1363-1

Other articles of this Issue 4/2004

Diabetologia 4/2004 Go to the issue

Article

Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes

Article

Genes for systemic vascular complications are differentially expressed in the livers of Type 2 diabetic patients

Short Communication

Brain energy metabolism during hypoglycaemia in healthy and Type 1 diabetic subjects

Comment

—to: Gardiner TA, Anderson HR, Degenhardt T et al. (2003) Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. Diabetologia 46:1269–1275

Article

Vascular endothelial cadherin and β-catenin in human fetoplacental vessels of pregnancies complicated by Type 1 diabetes: associations with angiogenesis and perturbed barrier function

Article

Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits